Tirzepatide Sequence

Tirzepatide represents a major evolution in incretin mimetic research as a synthetic 39-amino-acid peptide engineered for dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonism. This guide details the complete tirzepatide sequence, primary chemical parameters, structural modifications, and analytical standards required for rigorous in vitro and preclinical research applications.

GMP-compliant U.S. facilities
ISO 17025 third-party COAs
100% domestic — no imports
Fast tracked domestic shipping
Shop research peptides

Quick answer

Tirzepatide represents a major evolution in incretin mimetic research as a synthetic 39-amino-acid peptide engineered for dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonism. This guide details the complete tirzepatide sequence, primary chemical parameters, structural modifications, and analytical standards required for rigorous in vitro and preclinical research applications.

Reviewed by PX1 Research scientific team

Key takeaways

  • The [tirzepatide](/research-peptides/tirzepatide) sequence is a engineered 39-amino-acid linear peptide backbone modeled primarily on the native human GIP sequence, modified to confer dual affinity for both GIP and GLP-1 receptors.
  • Determining the exact molecular weight and chemical composition of the [tirzepatide](/research-peptides/tirzepatide) sequence is essential for molar concentration calculations, mass spectrometry calibration, and HPLC retention profile validation.
  • Preclinical binding assays indicate that the [tirzepatide](/research-peptides/tirzepatide) sequence acts as an unbalanced dual agonist.
  • To understand the structural modifications that grant multi-receptor affinity, researchers frequently benchmark the [tirzepatide](/research-peptides/tirzepatide) sequence against mono-agonists and emerging tri-agonists within the incretin family.

Primary Amino Acid Sequence and Structural Architecture

The tirzepatide sequence is a engineered 39-amino-acid linear peptide backbone modeled primarily on the native human GIP sequence, modified to confer dual affinity for both GIP and GLP-1 receptors. The canonical primary sequence is: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20-fatty diacid acyl linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2. It incorporates non-canonical amino acids, specifically alpha-aminobutyric acid (Aib) at positions 2 and 13, which protect the peptide chain against rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).

A defining structural feature of the tirzepatide sequence is the covalent attachment of a C20 fatty diacid acyl chain to the epsilon-amino group of the Lysine residue at position 20 via a gamma-glutamyl linker. This lipophilic acylation enhances reversible binding to plasma albumin in preclinical models, significantly extending the terminal elimination half-life during in vivo rodent studies. Researchers investigating receptor kinetics often analyze how this acylation alters steric access to transmembrane domains compared to non-acylated research peptides. For high-throughput assays, utilizing pure tirzepatide reference material ensures predictable binding kinetics across experimental replicates.

Molecular Weight, Chemical Formula, and Analytical Specifications

Determining the exact molecular weight and chemical composition of the tirzepatide sequence is essential for molar concentration calculations, mass spectrometry calibration, and HPLC retention profile validation. The key chemical parameters for research-grade tirzepatide include:

• Chemical Formula: C225H348N48O68 • Monoisotopic Mass: ~4810.52 Da • Molecular Weight (Average): 4813.53 g/mol • CAS Registry Number: 2023788-19-2 • Peptide Sequence Length: 39 amino acid residues with C-terminal amidation • Modifications: Aib2, Aib13, Lys20-(gamma-Glu-C20 fatty diacid), C-terminal amide

Due to the structural complexity of the 39-mer sequence combined with the bulky C20 fatty acid moiety, analytical verification requires robust reverse-phase high-performance liquid chromatography (RP-HPLC) paired with electrospray ionization mass spectrometry (ESI-MS). Laboratory assays dependent on absolute molecular weight parameters rely on high-resolution mass spectra to confirm the absence of truncated sequences or un-acylated side products.

Dual GIP/GLP-1 Receptor Binding Kinematics in Preclinical Models

Preclinical binding assays indicate that the tirzepatide sequence acts as an unbalanced dual agonist. It exhibits equal potency to native GIP at the GIP receptor, while displaying approximately 5-fold weaker potency at the GLP-1 receptor compared to endogenous GLP-1. In vitro cell-based reporter assays demonstrate that this biased signaling profile promotes robust cyclic adenosine monophosphate (cAMP) accumulation with lower rates of GLP-1 receptor internalisation and beta-arrestin recruitment.

When evaluating cellular responses, investigators compare dual agonists against selective mono-agonists to decipher downstream signaling pathways. Studies focusing on GIP and GLP-1 dual agonists highlight how simultaneous engagement of both receptor populations in pancreatic beta-cell models enhances insulin secretion dynamics beyond GLP-1 activation alone.

Comparative Structural Analysis: Tirzepatide vs. Related Incretin Peptides

To understand the structural modifications that grant multi-receptor affinity, researchers frequently benchmark the tirzepatide sequence against mono-agonists and emerging tri-agonists within the incretin family. Below is a comparative overview of key peptide sequences evaluated in metabolic research:

While semaglutide is a 31-amino-acid mono-agonist optimized exclusively for the GLP-1 receptor via a C18 fatty acid chain at position 26, the tirzepatide sequence integrates a 39-amino-acid GIP-based backbone with a longer C20 diacid chain. Furthermore, advanced multi-agonists like retatrutide extend this poly-pharmacology even further by incorporating glucagon receptor binding capabilities alongside GIP and GLP-1 targets. Early baseline structures such as liraglutide provided the initial proof-of-concept for fatty acid acylation, but lack the structural modifications (such as Aib insertion) that allow dual-receptor activation.

PX1 Research Quality Criteria and Analytical Benchmarks

To ensure reproducible data across cell culture systems and animal models, researchers require rigorous analytical verification of synthetic peptides. PX1 Research enforces strict quality assurance protocols for every lot of research compound supplied to accredited institutions:

• Purity Verification: ≥98% purity confirmed by analytical RP-HPLC. • Identity Confirmation: Matrix-assisted laser desorption/ionization (MALDI-TOF) or ESI-MS mass spectrometry matching theoretical molecular mass (4813.53 Da). • Endotoxin Testing: Verified below stringent limits (<0.05 EU/mg) via Chromogenic LAL assay for cell culture safety. • Manufacturing Origin: Synthesized in ISO 17025 accredited and GMP-compliant facilities within the USA. • Lot Traceability: Certificate of Analysis (COA) provided per individual lot with complete raw chromatograms. • Fulfillment Integrity: Rapid cold-chain distribution with same-day shipping M–F from California and Arizona logistics hubs.

Investigators interested in bulk procurement for multi-phase laboratory studies can access custom volume parameters through our dedicated wholesale program.

Laboratory Reconstitution and Solubilization Protocols

Because the tirzepatide sequence incorporates a hydrophobic C20 diacid chain, proper solubilization techniques are vital to prevent aggregation and maintain bioactivity in aqueous buffers. Standard laboratory protocols call for reconstituting lyophilized tirzepatide in sterile, non-pyrogenic Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4).

To achieve full dissolution, researchers should allow the vial to equilibrate to room temperature before introducing the solvent along the internal glass wall. Gentle swirly or slow inversion is recommended; vigorous vortexing must be avoided to prevent mechanical shear stress and peptide denaturation. For exact solvent-to-mass calculations, utilize our interactive peptide reconstitution calculator.

Storage Conditions and Aliquoting Parameters

Lyophilized powder containing the tirzepatide sequence exhibits high chemical stability when stored under desiccation at -20°C to -80°C, protected from light exposure. Under these conditions, the un-reconstituted peptide maintains target purity parameters for up to 24 months.

Once reconstituted into aqueous liquid media, working aliquots should be prepared to prevent repeated freeze-thaw cycles, which degrade the tertiary peptide structure and promote hydrolysis of the acyl chain. Reconstituted solution aliquots are stable at 4°C for up to 14 days, or at -80°C for up to 3 months. Detailed environmental stability matrices can be reviewed in our comprehensive peptide storage guidelines.

In Vitro and Preclinical Research Applications

The synthetic tirzepatide sequence serves as a pivotal tool in bio-molecular research investigating metabolic receptor cross-talk, beta-cell preservation, and lipid oxidation cascades. Key laboratory application domains include:

• Receptor Internalization Assays: Quantifying arrestin recruitment and receptor recycling dynamics in CHO or HEK293 cell lines expressing GIPR and GLP-1R. • Transcriptomic Profiling: Measuring up-regulation of insulin gene transcription factors (e.g., Pdx1, MafA) in isolated pancreatic islet models. • Central Nervous System Signaling: Mapping arcuate nucleus neuronal activation via c-Fos expression in rodent brain tissue slice preparations. • Energy Expenditure Research: Analyzing metabolic rate and mitochondrial uncoupling protein (UCP1) expression in brown adipose tissue (BAT) cultures.

Researchers seeking broader context on structural classes can review our comprehensive hub covering all available incretin mimetics overview or browse our complete library of all peptides.

Frequently Asked Questions

What is the exact tirzepatide sequence?

The tirzepatide sequence is a 39-amino-acid synthetic peptide: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20-fatty diacid acyl linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.

What is the molecular weight of tirzepatide?

The average molecular weight of tirzepatide is approximately 4813.53 g/mol, with a monoisotopic mass of ~4810.52 Da, accounting for its 39 amino acids, C20 fatty diacid linker, and C-terminal amidation.

How do non-canonical amino acids affect the tirzepatide sequence?

The incorporation of alpha-aminobutyric acid (Aib) at positions 2 and 13 prevents cleavage by dipeptidyl peptidase-4 (DPP-4), significantly increasing enzymatic stability in preclinical research models.

What solvent is recommended for reconstituting tirzepatide for lab assays?

For standard laboratory assays, tirzepatide is typically reconstituted in sterile Bacteriostatic Water or phosphate-buffered saline (PBS, pH 7.4). Swirl gently to dissolve and avoid high-shear vortexing.

How should reconstituted tirzepatide be stored in the lab?

Reconstituted tirzepatide solutions should be aliquoted into single-use microcentrifuge tubes and stored at -80°C to avoid repeated freeze-thaw cycles. Short-term storage at 4°C is viable for up to 14 days.

What receptor targets are activated by the tirzepatide sequence?

In vitro binding studies confirm that tirzepatide acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.

How does tirzepatide differ structurally from semaglutide?

Tirzepatide is a 39-amino-acid dual GIP/GLP-1 agonist with a C20 diacid linker at position 20, whereas semaglutide is a 31-amino-acid GLP-1 mono-agonist carrying a C18 diacid chain at position 26.

What purity levels are provided with PX1 Research tirzepatide?

PX1 Research supplies tirzepatide at ≥98% purity verified via RP-HPLC and ESI-MS, accompanied by a lot-specific Certificate of Analysis (COA) and endotoxin testing (<0.05 EU/mg).

Is PX1 Research tirzepatide synthesized in the USA?

Yes. All PX1 Research peptides are manufactured in ISO 17025 accredited, GMP-compliant facilities located in the USA, and shipped directly from California and Arizona hubs.

Can tirzepatide sequence material be ordered for institutional bulk research?

Yes, high-purity tirzepatide sequence material can be procured in custom quantities and batch sizes through the PX1 Research wholesale program.

Related pages

All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.